Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PFQU | ISIN: US6748705067 | Ticker-Symbol: RUOC
Tradegate
04.11.24
20:41 Uhr
0,138 Euro
+0,001
+0,88 %
1-Jahres-Chart
OCEAN POWER TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
OCEAN POWER TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0970,17804.11.
0,1320,14104.11.
ACCESSWIRE
560 Leser
Artikel bewerten:
(2)

Paragon Technologies Inc.: Ocean Power Continues to Ignore Small Individual Investors Instead Focusing on Institutional Investors Who Own Relatively Little OPT Stock

EASTON, PA / ACCESSWIRE / February 27, 2024 / Paragon Technologies, Inc. ("Paragon"), a diversified holding company, and the largest shareholders of Ocean Power Technologies, Inc. (NYSE American:OPTT), ("Company") ("OPT"), is dismayed at how OPT's Board and CEO continue to disregard individual shareholders and instead favor institutional investors who own relatively little OPT shares.

"By our estimate institutional investors, in total, own about 4-5% of OPT, while the remaining 95% of shares are held by individual investors," notes Sham Gad, Chairman of Paragon Technologies. "Yet in announcing its upcoming earnings release OPT now wants to hear from and speak to portfolio managers."

"What about listening to the individual investors who have funded OPT with tens of millions of dollars from new equity sales that have funded OPT's growing losses and paid for growing board and executive compensation?" asks Gad. "And in return those shareholders have been rewarded with a 90% decline in share price as a result of an incompetent and failing strategy by the Board and CEO."

The stark reality is that with a market cap of approximately $17 million, institutional investors are likely not interested in OPT. Analysts have nothing to say about a business that has had the disastrous financial failings that OPT has had over the years.

The stock market is going up. OPT shares are going down. And because OPT's CEO and Board know they have failed shareholders every single day, they ignore them.

Perhaps the most egregious indication of the little to no regard OPT has for its individual investors is the robo-calls and spam-like emails OPT is annoying shareholders with everyday asking them to vote for their failed slate of candidates.

CEO Stratmann cannot take the time to personally call his individual shareholders and talk about his supposed "working" strategy and explain why he and the board deserve their vote after failing them for years.

But OPT is more than happy to chat to institutional investors who invest other people's money and are not feeling the financial pain that individual investors have suffered.

Instead of working constructively with Paragon - OPT's single largest shareholder - to reinvigorate OPT, the Board continues to spend millions putting up roadblocks to deny shareholders the opportunity to benefit from Paragon's nominees' experience, ideas, and track record. As Paragon has stated from day one, our sole objective is to drive a sustainable increase in shareholder value and we remain open to working existing directors in order to put ALL OPT shareholders first.

Paragon urges OPT shareholders to continue showing the OPT directors and executives that you will not be duped and misled about the state of OPT and ignore any and all messages from OPT asking you to vote the white proxy card. Do not let this Board get away with another year of destroying shareholder value.

If you have voted in ANY WAY on the white proxy, you should revote the BLUE proxy to save your investment from a likely total loss.

If you have NOT YET VOTED, we urge you to ignore any and all calls or emails from OPT and completely disregard the white proxy and cast your vote on the BLUE proxy.

Please email us at ir@pgntgroup.com with any questions about how to vote your BLUE proxy card.

We appreciate the support from shareholders thus far. If shareholders have any questions, please contact our Proxy Solicitor, Alliance Advisors at:

Alliance Advisors
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003
Toll-Free Phone: 855-200-8651
Email: OPTT@allianceadvisors.com

No matter how many shares you hold, we would like to hear from you. Please email us at ir@pgntgroup.com if you need any help in voting your BLUE proxy.

By voting on Paragon's BLUE universal proxy card, you can send a message to OPT that you do not support their actions in relation to the Annual Meeting and attempting to block the recognition of Paragon's nominees.

OPT has said that it will disregard proxy votes in favor of Paragon's director nominees. Whether OPT may lawfully disregard Paragon's director nominees is an issue that Paragon expects will be resolved by the Delaware courts.

Stockholders should review the section of Paragon's proxy statement titled "Questions And Answers Relating To This Proxy Solicitation--Why is OPT saying it will disregard Paragon's director nominations, and how does that impact proxies that stockholders provide to Paragon?"

Paragon Technologies, Inc., together with the other participants named herein, has filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement and an accompanying proxy card soliciting votes for the election of director nominees at the 2023 annual meeting of shareholders of Ocean Power Technologies, Inc., a Delaware corporation (the "company").

Paragon Technologies, Inc. is the beneficial owner of 2,472,011 shares of common stock of the company, par value $0.001 per share ("common stock").

Paragon Technologies, Inc., and Paragon's director nominees Hesham M. Gad, Shawn M. Harpen, Jack H. Jacobs, and Samuel S. Weiser, are the participants in the proxy solicitation. Mr. Gad, Executive Chairman of Paragon's Board of Directors and Chief Executive Officer of Paragon, and Messrs. Jacobs and Weiser, directors of Paragon, may be deemed to beneficially own the shares of the company's common stock held by Paragon. Ms. Harpen does not own beneficially or of record any securities of the company. Updated information regarding the participants and their direct and indirect interests in the solicitation, by security holdings or otherwise, has been and will be included in Paragon's proxy statement and other materials filed with the SEC.

SHAREHOLDERS OF THE COMPANY SHOULD READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION RELATING TO THE COMPANY'S ANNUAL MEETING, PARAGON'S SOLICITATION OF PROXIES AND PARAGON'S NOMINEES TO THE BOARD. SUCH PROXY MATERIALS ARE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT WWW.SEC.GOV OR FROM PARAGON TECHNOLOGIES, INC. REQUESTS FOR COPIES SHOULD BE DIRECTED TO PARAGON'S PROXY SOLICITOR.

SOURCE: Paragon Technologies Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.